Please assess the completion status of the following clinical trial:

Trial Title: Therapy Optimization in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older, with a diagnosis of MS.~* Being treated with Glatiramer Acetate (GA) or (IFN)-β~* Receiving therapy from a participating Specialty Pharmacy~Exclusion Criteria:~* Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study~* Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)~* Unlikely to be able to participate for the full two years of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated MS Subjects (Type: None): Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies

Based on this trial design, predict the completion outcome and termination type (if applicable).